ID DOCK9_HUMAN Reviewed; 2069 AA. AC Q9BZ29; B3KX25; E9PFM9; Q5JUD4; Q5JUD6; Q5T2Q1; Q5TAN8; Q9BZ25; Q9BZ26; AC Q9BZ27; Q9BZ28; Q9UPU4; DT 19-OCT-2002, integrated into UniProtKB/Swiss-Prot. DT 19-OCT-2002, sequence version 2. DT 24-JAN-2024, entry version 185. DE RecName: Full=Dedicator of cytokinesis protein 9 {ECO:0000305}; DE AltName: Full=Cdc42 guanine nucleotide exchange factor zizimin-1 {ECO:0000305}; DE Short=Zizimin-1 {ECO:0000305}; GN Name=DOCK9 {ECO:0000312|HGNC:HGNC:14132}; GN Synonyms=KIAA1058, ZIZ1 {ECO:0000305}; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE (ISOFORM 1), FUNCTION, INTERACTION WITH CDC42, GEF RP ACTIVITY, AND TISSUE SPECIFICITY. RX PubMed=12172552; DOI=10.1038/ncb835; RA Meller N., Irani-Tehrani M., Kiosses W.B., Del Pozo M.A., Schwartz M.A.; RT "Zizimin1, a novel Cdc42 activator, reveals a new GEF domain for Rho RT proteins."; RL Nat. Cell Biol. 4:639-647(2002). RN [2] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2). RC TISSUE=Brain; RX PubMed=10470851; DOI=10.1093/dnares/6.3.197; RA Kikuno R., Nagase T., Ishikawa K., Hirosawa M., Miyajima N., Tanaka A., RA Kotani H., Nomura N., Ohara O.; RT "Prediction of the coding sequences of unidentified human genes. XIV. The RT complete sequences of 100 new cDNA clones from brain which code for large RT proteins in vitro."; RL DNA Res. 6:197-205(1999). RN [3] RP SEQUENCE REVISION. RX PubMed=12168954; DOI=10.1093/dnares/9.3.99; RA Nakajima D., Okazaki N., Yamakawa H., Kikuno R., Ohara O., Nagase T.; RT "Construction of expression-ready cDNA clones for KIAA genes: manual RT curation of 330 KIAA cDNA clones."; RL DNA Res. 9:99-106(2002). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 5). RC TISSUE=Uterus; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [5] RP NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA] (ISOFORMS 1; 2; 3 AND 4). RX PubMed=15057823; DOI=10.1038/nature02379; RA Dunham A., Matthews L.H., Burton J., Ashurst J.L., Howe K.L., RA Ashcroft K.J., Beare D.M., Burford D.C., Hunt S.E., Griffiths-Jones S., RA Jones M.C., Keenan S.J., Oliver K., Scott C.E., Ainscough R., Almeida J.P., RA Ambrose K.D., Andrews D.T., Ashwell R.I.S., Babbage A.K., Bagguley C.L., RA Bailey J., Bannerjee R., Barlow K.F., Bates K., Beasley H., Bird C.P., RA Bray-Allen S., Brown A.J., Brown J.Y., Burrill W., Carder C., Carter N.P., RA Chapman J.C., Clamp M.E., Clark S.Y., Clarke G., Clee C.M., Clegg S.C., RA Cobley V., Collins J.E., Corby N., Coville G.J., Deloukas P., Dhami P., RA Dunham I., Dunn M., Earthrowl M.E., Ellington A.G., Faulkner L., RA Frankish A.G., Frankland J., French L., Garner P., Garnett J., RA Gilbert J.G.R., Gilson C.J., Ghori J., Grafham D.V., Gribble S.M., RA Griffiths C., Hall R.E., Hammond S., Harley J.L., Hart E.A., Heath P.D., RA Howden P.J., Huckle E.J., Hunt P.J., Hunt A.R., Johnson C., Johnson D., RA Kay M., Kimberley A.M., King A., Laird G.K., Langford C.J., Lawlor S., RA Leongamornlert D.A., Lloyd D.M., Lloyd C., Loveland J.E., Lovell J., RA Martin S., Mashreghi-Mohammadi M., McLaren S.J., McMurray A., Milne S., RA Moore M.J.F., Nickerson T., Palmer S.A., Pearce A.V., Peck A.I., Pelan S., RA Phillimore B., Porter K.M., Rice C.M., Searle S., Sehra H.K., Shownkeen R., RA Skuce C.D., Smith M., Steward C.A., Sycamore N., Tester J., Thomas D.W., RA Tracey A., Tromans A., Tubby B., Wall M., Wallis J.M., West A.P., RA Whitehead S.L., Willey D.L., Wilming L., Wray P.W., Wright M.W., Young L., RA Coulson A., Durbin R.M., Hubbard T., Sulston J.E., Beck S., Bentley D.R., RA Rogers J., Ross M.T.; RT "The DNA sequence and analysis of human chromosome 13."; RL Nature 428:522-528(2004). RN [6] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 1551-2069 (ISOFORM 4). RC TISSUE=Eye; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [7] RP NOMENCLATURE, AND GEF ACTIVITY. RX PubMed=12432077; DOI=10.1242/jcs.00219; RA Cote J.-F., Vuori K.; RT "Identification of an evolutionarily conserved superfamily of DOCK180- RT related proteins with guanine nucleotide exchange activity."; RL J. Cell Sci. 115:4901-4913(2002). RN [8] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-1241, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=16964243; DOI=10.1038/nbt1240; RA Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; RT "A probability-based approach for high-throughput protein phosphorylation RT analysis and site localization."; RL Nat. Biotechnol. 24:1285-1292(2006). RN [9] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-21, AND IDENTIFICATION BY RP MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=18669648; DOI=10.1073/pnas.0805139105; RA Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E., RA Elledge S.J., Gygi S.P.; RT "A quantitative atlas of mitotic phosphorylation."; RL Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). RN [10] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-1235 AND THR-1241, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Cervix carcinoma; RX PubMed=20068231; DOI=10.1126/scisignal.2000475; RA Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L., RA Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.; RT "Quantitative phosphoproteomics reveals widespread full phosphorylation RT site occupancy during mitosis."; RL Sci. Signal. 3:RA3-RA3(2010). RN [11] RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RX PubMed=21269460; DOI=10.1186/1752-0509-5-17; RA Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T., RA Bennett K.L., Superti-Furga G., Colinge J.; RT "Initial characterization of the human central proteome."; RL BMC Syst. Biol. 5:17-17(2011). RN [12] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-21; SER-32; SER-927; SER-1255 RP AND SER-1264, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE RP ANALYSIS]. RC TISSUE=Cervix carcinoma, and Erythroleukemia; RX PubMed=23186163; DOI=10.1021/pr300630k; RA Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J., RA Mohammed S.; RT "Toward a comprehensive characterization of a human cancer cell RT phosphoproteome."; RL J. Proteome Res. 12:260-271(2013). RN [13] RP PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-167 AND SER-170, AND RP IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS]. RC TISSUE=Liver; RX PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014; RA Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L., RA Ye M., Zou H.; RT "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver RT phosphoproteome."; RL J. Proteomics 96:253-262(2014). RN [14] RP STRUCTURE BY NMR OF 165-301. RG RIKEN structural genomics initiative (RSGI); RT "Solution structure of pleckstrin homology domain from human KIAA1058 RT protein."; RL Submitted (NOV-2004) to the PDB data bank. RN [15] RP X-RAY CRYSTALLOGRAPHY (2.2 ANGSTROMS) OF 1605-2069 IN COMPLEX WITH CDC42, RP FUNCTION, AND SUBUNIT. RX PubMed=19745154; DOI=10.1126/science.1174468; RA Yang J., Zhang Z., Roe S.M., Marshall C.J., Barford D.; RT "Activation of Rho GTPases by DOCK exchange factors is mediated by a RT nucleotide sensor."; RL Science 325:1398-1402(2009). CC -!- FUNCTION: Guanine nucleotide-exchange factor (GEF) that activates CDC42 CC by exchanging bound GDP for free GTP. Overexpression induces filopodia CC formation. {ECO:0000269|PubMed:12172552, ECO:0000269|PubMed:19745154}. CC -!- SUBUNIT: Homodimer (Probable). Interacts preferentially with CC nucleotide-depleted CDC42. {ECO:0000269|PubMed:12172552, CC ECO:0000269|PubMed:19745154, ECO:0000305}. CC -!- INTERACTION: CC Q9BZ29; Q15796: SMAD2; NbExp=3; IntAct=EBI-2695893, EBI-1040141; CC Q9BZ29; P84022: SMAD3; NbExp=3; IntAct=EBI-2695893, EBI-347161; CC -!- SUBCELLULAR LOCATION: Endomembrane system {ECO:0000305}. CC Note=Associated with membranes. {ECO:0000305}. CC -!- ALTERNATIVE PRODUCTS: CC Event=Alternative splicing; Named isoforms=5; CC Name=1; CC IsoId=Q9BZ29-1; Sequence=Displayed; CC Name=2; CC IsoId=Q9BZ29-5; Sequence=VSP_017128; CC Name=3; CC IsoId=Q9BZ29-3; Sequence=VSP_004024; CC Name=4; CC IsoId=Q9BZ29-4; Sequence=VSP_007709, VSP_007710; CC Name=5; CC IsoId=Q9BZ29-6; Sequence=VSP_017128, VSP_045683, VSP_045684; CC -!- TISSUE SPECIFICITY: Widely expressed, with highest expression in heart CC and placenta. Expressed at intermediate level in kidney, brain, lung CC and skeletal muscle. {ECO:0000269|PubMed:12172552}. CC -!- DOMAIN: The DOCKER domain is necessary and sufficient for the GEF CC activity. CC -!- MISCELLANEOUS: 'Zizim' means 'spike' in Hebrew. {ECO:0000305}. CC -!- MISCELLANEOUS: [Isoform 4]: Produced by exon skipping that results in a CC frameshift. {ECO:0000305}. CC -!- SIMILARITY: Belongs to the DOCK family. {ECO:0000255|PROSITE- CC ProRule:PRU00983}. CC -!- SEQUENCE CAUTION: CC Sequence=BAA83010.2; Type=Erroneous initiation; Evidence={ECO:0000305}; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; AF527605; AAM90306.1; -; mRNA. DR EMBL; AB028981; BAA83010.2; ALT_INIT; mRNA. DR EMBL; AK126492; BAG54337.1; -; mRNA. DR EMBL; AL139084; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL161420; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; AL391122; -; NOT_ANNOTATED_CDS; Genomic_DNA. DR EMBL; BC043506; AAH43506.1; -; mRNA. DR CCDS; CCDS45062.1; -. [Q9BZ29-5] DR CCDS; CCDS45063.1; -. [Q9BZ29-6] DR CCDS; CCDS91829.1; -. [Q9BZ29-1] DR RefSeq; NP_001123520.1; NM_001130048.1. [Q9BZ29-5] DR RefSeq; NP_001123521.1; NM_001130049.1. DR RefSeq; NP_001123522.1; NM_001130050.1. [Q9BZ29-6] DR RefSeq; NP_001305778.1; NM_001318849.1. DR RefSeq; NP_056111.1; NM_015296.2. [Q9BZ29-1] DR PDB; 1WG7; NMR; -; A=165-301. DR PDB; 2WM9; X-ray; 2.20 A; A=1605-2067. DR PDB; 2WMN; X-ray; 2.39 A; A=1605-2067. DR PDB; 2WMO; X-ray; 2.20 A; A=1605-2067. DR PDBsum; 1WG7; -. DR PDBsum; 2WM9; -. DR PDBsum; 2WMN; -. DR PDBsum; 2WMO; -. DR AlphaFoldDB; Q9BZ29; -. DR SMR; Q9BZ29; -. DR BioGRID; 116930; 59. DR IntAct; Q9BZ29; 28. DR MINT; Q9BZ29; -. DR STRING; 9606.ENSP00000365643; -. DR GlyGen; Q9BZ29; 1 site, 1 O-linked glycan (1 site). DR iPTMnet; Q9BZ29; -. DR PhosphoSitePlus; Q9BZ29; -. DR BioMuta; DOCK9; -. DR DMDM; 24212635; -. DR EPD; Q9BZ29; -. DR jPOST; Q9BZ29; -. DR MassIVE; Q9BZ29; -. DR MaxQB; Q9BZ29; -. DR PaxDb; 9606-ENSP00000365643; -. DR PeptideAtlas; Q9BZ29; -. DR ProteomicsDB; 20137; -. DR ProteomicsDB; 79758; -. [Q9BZ29-1] DR ProteomicsDB; 79759; -. [Q9BZ29-3] DR ProteomicsDB; 79760; -. [Q9BZ29-4] DR ProteomicsDB; 79761; -. [Q9BZ29-5] DR Pumba; Q9BZ29; -. DR Antibodypedia; 25029; 79 antibodies from 17 providers. DR DNASU; 23348; -. DR Ensembl; ENST00000376460.5; ENSP00000365643.1; ENSG00000088387.22. [Q9BZ29-5] DR Ensembl; ENST00000627024.2; ENSP00000487551.1; ENSG00000088387.22. [Q9BZ29-6] DR Ensembl; ENST00000652315.1; ENSP00000498761.1; ENSG00000088387.22. [Q9BZ29-1] DR GeneID; 23348; -. DR KEGG; hsa:23348; -. DR UCSC; uc058xyj.1; human. [Q9BZ29-1] DR AGR; HGNC:14132; -. DR CTD; 23348; -. DR DisGeNET; 23348; -. DR GeneCards; DOCK9; -. DR HGNC; HGNC:14132; DOCK9. DR HPA; ENSG00000088387; Low tissue specificity. DR MIM; 607325; gene. DR neXtProt; NX_Q9BZ29; -. DR OpenTargets; ENSG00000088387; -. DR PharmGKB; PA134877754; -. DR VEuPathDB; HostDB:ENSG00000088387; -. DR eggNOG; KOG1997; Eukaryota. DR GeneTree; ENSGT00940000155972; -. DR InParanoid; Q9BZ29; -. DR OrthoDB; 5480873at2759; -. DR PhylomeDB; Q9BZ29; -. DR TreeFam; TF313629; -. DR PathwayCommons; Q9BZ29; -. DR Reactome; R-HSA-9013148; CDC42 GTPase cycle. DR Reactome; R-HSA-9013149; RAC1 GTPase cycle. DR Reactome; R-HSA-983231; Factors involved in megakaryocyte development and platelet production. DR SignaLink; Q9BZ29; -. DR BioGRID-ORCS; 23348; 10 hits in 1155 CRISPR screens. DR ChiTaRS; DOCK9; human. DR EvolutionaryTrace; Q9BZ29; -. DR GeneWiki; Dock9; -. DR GenomeRNAi; 23348; -. DR Pharos; Q9BZ29; Tbio. DR PRO; PR:Q9BZ29; -. DR Proteomes; UP000005640; Chromosome 13. DR RNAct; Q9BZ29; Protein. DR Bgee; ENSG00000088387; Expressed in calcaneal tendon and 207 other cell types or tissues. DR ExpressionAtlas; Q9BZ29; baseline and differential. DR GO; GO:0005829; C:cytosol; TAS:Reactome. DR GO; GO:0012505; C:endomembrane system; IEA:UniProtKB-SubCell. DR GO; GO:0016020; C:membrane; HDA:UniProtKB. DR GO; GO:0045296; F:cadherin binding; HDA:BHF-UCL. DR GO; GO:0005085; F:guanyl-nucleotide exchange factor activity; ISS:UniProtKB. DR GO; GO:0043547; P:positive regulation of GTPase activity; ISS:UniProtKB. DR GO; GO:0007264; P:small GTPase mediated signal transduction; IEA:InterPro. DR CDD; cd08697; C2_Dock-D; 1. DR CDD; cd11698; DHR2_DOCK9; 1. DR CDD; cd13267; PH_DOCK-D; 1. DR Gene3D; 1.20.58.740; -; 1. DR Gene3D; 1.25.40.410; -; 1. DR Gene3D; 2.60.40.150; C2 domain; 1. DR Gene3D; 2.30.29.30; Pleckstrin-homology domain (PH domain)/Phosphotyrosine-binding domain (PTB); 1. DR InterPro; IPR016024; ARM-type_fold. DR InterPro; IPR037809; C2_Dock-D. DR InterPro; IPR027007; C2_DOCK-type_domain. DR InterPro; IPR035892; C2_domain_sf. DR InterPro; IPR026791; DOCK. DR InterPro; IPR021816; DOCK_C/D_N. DR InterPro; IPR043161; DOCK_C_lobe_A. DR InterPro; IPR043162; DOCK_C_lobe_C. DR InterPro; IPR027357; DOCKER_dom. DR InterPro; IPR046769; DOCKER_Lobe_A. DR InterPro; IPR046770; DOCKER_Lobe_B. DR InterPro; IPR046773; DOCKER_Lobe_C. DR InterPro; IPR011993; PH-like_dom_sf. DR InterPro; IPR001849; PH_domain. DR PANTHER; PTHR23317; DEDICATOR OF CYTOKINESIS DOCK; 1. DR PANTHER; PTHR23317:SF77; DEDICATOR OF CYTOKINESIS PROTEIN 9; 1. DR Pfam; PF06920; DHR-2_Lobe_A; 1. DR Pfam; PF20422; DHR-2_Lobe_B; 1. DR Pfam; PF20421; DHR-2_Lobe_C; 1. DR Pfam; PF14429; DOCK-C2; 1. DR Pfam; PF11878; DOCK_C-D_N; 1. DR Pfam; PF00169; PH; 1. DR SMART; SM00233; PH; 1. DR SUPFAM; SSF48371; ARM repeat; 1. DR SUPFAM; SSF50729; PH domain-like; 1. DR PROSITE; PS51650; C2_DOCK; 1. DR PROSITE; PS51651; DOCKER; 1. DR PROSITE; PS50003; PH_DOMAIN; 1. DR Genevisible; Q9BZ29; HS. PE 1: Evidence at protein level; KW 3D-structure; Alternative splicing; Coiled coil; KW Guanine-nucleotide releasing factor; Membrane; Phosphoprotein; KW Reference proteome; Repeat. FT CHAIN 1..2069 FT /note="Dedicator of cytokinesis protein 9" FT /id="PRO_0000189999" FT DOMAIN 174..281 FT /note="PH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00145" FT DOMAIN 640..818 FT /note="C2 DOCK-type" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00983" FT DOMAIN 1605..2069 FT /note="DOCKER" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00984" FT REGION 290..313 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1241..1282 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT REGION 1693..2069 FT /note="Interaction with CDC42" FT /evidence="ECO:0000269|PubMed:12172552" FT COILED 1948..1982 FT /evidence="ECO:0000255" FT COILED 2034..2067 FT /evidence="ECO:0000255" FT COMPBIAS 290..306 FT /note="Basic and acidic residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT MOD_RES 21 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:18669648, FT ECO:0007744|PubMed:23186163" FT MOD_RES 32 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 167 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 170 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:24275569" FT MOD_RES 433 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8BIK4" FT MOD_RES 443 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8BIK4" FT MOD_RES 927 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1235 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:20068231" FT MOD_RES 1241 FT /note="Phosphothreonine" FT /evidence="ECO:0007744|PubMed:16964243, FT ECO:0007744|PubMed:20068231" FT MOD_RES 1255 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT MOD_RES 1261 FT /note="Phosphoserine" FT /evidence="ECO:0000250|UniProtKB:Q8BIK4" FT MOD_RES 1264 FT /note="Phosphoserine" FT /evidence="ECO:0007744|PubMed:23186163" FT VAR_SEQ 1..43 FT /note="MSQPPLLPASAETRKFTRALSKPGTAAELRQSVSEVVRGSVLL -> MQADK FT CRTSSRSVKKELVIESPLQYKDAAQGEVEAESPGPVP (in isoform 2 and FT isoform 5)" FT /evidence="ECO:0000303|PubMed:10470851, FT ECO:0000303|PubMed:14702039" FT /id="VSP_017128" FT VAR_SEQ 1234..1254 FT /note="ASPYTTSTPNINSVRNADSRG -> GNAPCSCGLLSTITLKVSWSQ (in FT isoform 5)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_045683" FT VAR_SEQ 1255..2069 FT /note="Missing (in isoform 5)" FT /evidence="ECO:0000303|PubMed:14702039" FT /id="VSP_045684" FT VAR_SEQ 1355..1378 FT /note="RTGMMHARLQQLGSLDNSLTFNHS -> SVRKISSVLGISVDNG (in FT isoform 3)" FT /evidence="ECO:0000305" FT /id="VSP_004024" FT VAR_SEQ 1791..1804 FT /note="Missing (in isoform 4)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_007709" FT VAR_SEQ 2068..2069 FT /note="LG -> ICPLEEKTSVLPNSLHIFNAISGTPTSTMVHGMTSSSSVV (in FT isoform 4)" FT /evidence="ECO:0000303|PubMed:15489334" FT /id="VSP_007710" FT VARIANT 455 FT /note="A -> T (in dbSNP:rs56010605)" FT /id="VAR_062000" FT VARIANT 1416 FT /note="K -> E (in dbSNP:rs16955934)" FT /id="VAR_053067" FT CONFLICT 170 FT /note="S -> P (in Ref. 4; BAG54337)" FT /evidence="ECO:0000305" FT CONFLICT 296 FT /note="S -> P (in Ref. 4; BAG54337)" FT /evidence="ECO:0000305" FT STRAND 178..183 FT /evidence="ECO:0007829|PDB:1WG7" FT HELIX 190..194 FT /evidence="ECO:0007829|PDB:1WG7" FT STRAND 198..206 FT /evidence="ECO:0007829|PDB:1WG7" FT STRAND 208..210 FT /evidence="ECO:0007829|PDB:1WG7" FT STRAND 212..220 FT /evidence="ECO:0007829|PDB:1WG7" FT STRAND 227..230 FT /evidence="ECO:0007829|PDB:1WG7" FT TURN 232..234 FT /evidence="ECO:0007829|PDB:1WG7" FT STRAND 248..252 FT /evidence="ECO:0007829|PDB:1WG7" FT STRAND 254..256 FT /evidence="ECO:0007829|PDB:1WG7" FT STRAND 258..262 FT /evidence="ECO:0007829|PDB:1WG7" FT HELIX 266..291 FT /evidence="ECO:0007829|PDB:1WG7" FT HELIX 1610..1628 FT /evidence="ECO:0007829|PDB:2WM9" FT HELIX 1631..1651 FT /evidence="ECO:0007829|PDB:2WM9" FT STRAND 1677..1679 FT /evidence="ECO:0007829|PDB:2WM9" FT HELIX 1682..1685 FT /evidence="ECO:0007829|PDB:2WM9" FT TURN 1686..1688 FT /evidence="ECO:0007829|PDB:2WM9" FT HELIX 1690..1695 FT /evidence="ECO:0007829|PDB:2WM9" FT STRAND 1708..1710 FT /evidence="ECO:0007829|PDB:2WM9" FT HELIX 1711..1727 FT /evidence="ECO:0007829|PDB:2WM9" FT HELIX 1731..1733 FT /evidence="ECO:0007829|PDB:2WM9" FT HELIX 1734..1738 FT /evidence="ECO:0007829|PDB:2WM9" FT TURN 1739..1741 FT /evidence="ECO:0007829|PDB:2WM9" FT HELIX 1742..1747 FT /evidence="ECO:0007829|PDB:2WM9" FT HELIX 1751..1774 FT /evidence="ECO:0007829|PDB:2WM9" FT STRAND 1781..1788 FT /evidence="ECO:0007829|PDB:2WM9" FT HELIX 1808..1810 FT /evidence="ECO:0007829|PDB:2WM9" FT STRAND 1814..1820 FT /evidence="ECO:0007829|PDB:2WM9" FT HELIX 1825..1840 FT /evidence="ECO:0007829|PDB:2WM9" FT HELIX 1842..1844 FT /evidence="ECO:0007829|PDB:2WM9" FT STRAND 1845..1848 FT /evidence="ECO:0007829|PDB:2WM9" FT HELIX 1856..1858 FT /evidence="ECO:0007829|PDB:2WM9" FT STRAND 1863..1873 FT /evidence="ECO:0007829|PDB:2WM9" FT HELIX 1877..1882 FT /evidence="ECO:0007829|PDB:2WM9" FT HELIX 1887..1889 FT /evidence="ECO:0007829|PDB:2WM9" FT STRAND 1890..1902 FT /evidence="ECO:0007829|PDB:2WM9" FT STRAND 1904..1909 FT /evidence="ECO:0007829|PDB:2WMO" FT TURN 1912..1914 FT /evidence="ECO:0007829|PDB:2WM9" FT STRAND 1916..1929 FT /evidence="ECO:0007829|PDB:2WM9" FT STRAND 1931..1945 FT /evidence="ECO:0007829|PDB:2WM9" FT HELIX 1947..1967 FT /evidence="ECO:0007829|PDB:2WM9" FT HELIX 1973..1984 FT /evidence="ECO:0007829|PDB:2WM9" FT STRAND 1987..1989 FT /evidence="ECO:0007829|PDB:2WM9" FT HELIX 1993..1999 FT /evidence="ECO:0007829|PDB:2WM9" FT HELIX 2013..2037 FT /evidence="ECO:0007829|PDB:2WM9" FT TURN 2041..2043 FT /evidence="ECO:0007829|PDB:2WM9" FT HELIX 2044..2064 FT /evidence="ECO:0007829|PDB:2WM9" SQ SEQUENCE 2069 AA; 236446 MW; 95073CD751745AAE CRC64; MSQPPLLPAS AETRKFTRAL SKPGTAAELR QSVSEVVRGS VLLAKPKLIE PLDYENVIVQ KKTQILNDCL REMLLFPYDD FQTAILRRQG RYICSTVPAK AEEEAQSLFV TECIKTYNSD WHLVNYKYED YSGEFRQLPN KVVKLDKLPV HVYEVDEEVD KDEDAASLGS QKGGITKHGW LYKGNMNSAI SVTMRSFKRR FFHLIQLGDG SYNLNFYKDE KISKEPKGSI FLDSCMGVVQ NNKVRRFAFE LKMQDKSSYL LAADSEVEME EWITILNKIL QLNFEAAMQE KRNGDSHEDD EQSKLEGSGS GLDSYLPELA KSAREAEIKL KSESRVKLFY LDPDAQKLDF SSAEPEVKSF EEKFGKRILV KCNDLSFNLQ CCVAENEEGP TTNVEPFFVT LSLFDIKYNR KISADFHVDL NHFSVRQMLA TTSPALMNGS GQSPSVLKGI LHEAAMQYPK QGIFSVTCPH PDIFLVARIE KVLQGSITHC AEPYMKSSDS SKVAQKVLKN AKQACQRLGQ YRMPFAWAAR TLFKDASGNL DKNARFSAIY RQDSNKLSND DMLKLLADFR KPEKMAKLPV ILGNLDITID NVSSDFPNYV NSSYIPTKQF ETCSKTPITF EVEEFVPCIP KHTQPYTIYT NHLYVYPKYL KYDSQKSFAK ARNIAICIEF KDSDEEDSQP LKCIYGRPGG PVFTRSAFAA VLHHHQNPEF YDEIKIELPT QLHEKHHLLL TFFHVSCDNS SKGSTKKRDV VETQVGYSWL PLLKDGRVVT SEQHIPVSAN LPSGYLGYQE LGMGRHYGPE IKWVDGGKPL LKISTHLVST VYTQDQHLHN FFQYCQKTES GAQALGNELV KYLKSLHAME GHVMIAFLPT ILNQLFRVLT RATQEEVAVN VTRVIIHVVA QCHEEGLESH LRSYVKYAYK AEPYVASEYK TVHEELTKSM TTILKPSADF LTSNKLLKYS WFFFDVLIKS MAQHLIENSK VKLLRNQRFP ASYHHAVETV VNMLMPHITQ KFRDNPEASK NANHSLAVFI KRCFTFMDRG FVFKQINNYI SCFAPGDPKT LFEYKFEFLR VVCNHEHYIP LNLPMPFGKG RIQRYQDLQL DYSLTDEFCR NHFLVGLLLR EVGTALQEFR EVRLIAISVL KNLLIKHSFD DRYASRSHQA RIATLYLPLF GLLIENVQRI NVRDVSPFPV NAGMTVKDES LALPAVNPLV TPQKGSTLDN SLHKDLLGAI SGIASPYTTS TPNINSVRNA DSRGSLISTD SGNSLPERNS EKSNSLDKHQ QSSTLGNSVV RCDKLDQSEI KSLLMCFLYI LKSMSDDALF TYWNKASTSE LMDFFTISEV CLHQFQYMGK RYIARTGMMH ARLQQLGSLD NSLTFNHSYG HSDADVLHQS LLEANIATEV CLTALDTLSL FTLAFKNQLL ADHGHNPLMK KVFDVYLCFL QKHQSETALK NVFTALRSLI YKFPSTFYEG RADMCAALCY EILKCCNSKL SSIRTEASQL LYFLMRNNFD YTGKKSFVRT HLQVIISVSQ LIADVVGIGG TRFQQSLSII NNCANSDRLI KHTSFSSDVK DLTKRIRTVL MATAQMKEHE NDPEMLVDLQ YSLAKSYAST PELRKTWLDS MARIHVKNGD LSEAAMCYVH VTALVAEYLT RKEAVQWEPP LLPHSHSACL RRSRGGVFRQ GCTAFRVITP NIDEEASMME DVGMQDVHFN EDVLMELLEQ CADGLWKAER YELIADIYKL IIPIYEKRRD FERLAHLYDT LHRAYSKVTE VMHSGRRLLG TYFRVAFFGQ AAQYQFTDSE TDVEGFFEDE DGKEYIYKEP KLTPLSEISQ RLLKLYSDKF GSENVKMIQD SGKVNPKDLD SKYAYIQVTH VIPFFDEKEL QERKTEFERS HNIRRFMFEM PFTQTGKRQG GVEEQCKRRT ILTAIHCFPY VKKRIPVMYQ HHTDLNPIEV AIDEMSKKVA ELRQLCSSAE VDMIKLQLKL QGSVSVQVNA GPLAYARAFL DDTNTKRYPD NKVKLLKEVF RQFVEACGQA LAVNERLIKE DQLEYQEEMK ANYREMAKEL SEIMHEQLG //